These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36467125)

  • 41. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
    Sukhram SD; Yilmaz G; Gu J
    Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.
    McAllister-Williams RH; Anderson IM; Finkelmeyer A; Gallagher P; Grunze HC; Haddad PM; Hughes T; Lloyd AJ; Mamasoula C; McColl E; Pearce S; Siddiqi N; Sinha BN; Steen N; Wainwright J; Winter FH; Ferrier IN; Watson S;
    Lancet Psychiatry; 2016 Feb; 3(2):117-27. PubMed ID: 26727041
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment.
    Edberg D; Hoppensteadt D; Walborn A; Fareed J; Sinacore J; Halaris A
    J Psychiatr Res; 2018 Jul; 102():1-7. PubMed ID: 29554535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis.
    Na KS; Lee KJ; Lee JS; Cho YS; Jung HY
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():79-85. PubMed ID: 24056287
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Baseline Serum Levels of Beclin-1, but Not Inflammatory Factors, May Predict Antidepressant Treatment Response in Chinese Han Patients With MDD: A Preliminary Study.
    He S; Zeng D; Xu F; Zhang J; Zhao N; Wang Q; Shi J; Lin Z; Yu W; Li H
    Front Psychiatry; 2019; 10():378. PubMed ID: 31244689
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Ridker PM; Devalaraja M; Baeres FMM; Engelmann MDM; Hovingh GK; Ivkovic M; Lo L; Kling D; Pergola P; Raj D; Libby P; Davidson M;
    Lancet; 2021 May; 397(10289):2060-2069. PubMed ID: 34015342
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
    Abbasi SH; Hosseini F; Modabbernia A; Ashrafi M; Akhondzadeh S
    J Affect Disord; 2012 Dec; 141(2-3):308-14. PubMed ID: 22516310
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression.
    Schmidt FM; Schröder T; Kirkby KC; Sander C; Suslow T; Holdt LM; Teupser D; Hegerl U; Himmerich H
    Psychiatry Res; 2016 May; 239():85-91. PubMed ID: 27137966
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice.
    De Berardis D; Fornaro M; Orsolini L; Iasevoli F; Tomasetti C; de Bartolomeis A; Serroni N; De Lauretis I; Girinelli G; Mazza M; Valchera A; Carano A; Vellante F; Matarazzo I; Perna G; Martinotti G; Di Giannantonio M
    CNS Spectr; 2017 Aug; 22(4):342-347. PubMed ID: 27702411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of recombinant erythropoietin on inflammatory markers in patients with affective disorders: A randomised controlled study.
    Vinberg M; Weikop P; Olsen NV; Kessing LV; Miskowiak K
    Brain Behav Immun; 2016 Oct; 57():53-57. PubMed ID: 27181179
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum Cortisol, Nesfatin-1, and IL-1β: Potential Diagnostic Biomarkers in Elderly Patients with Treatment-Resistant Depression.
    Wu X; Dai B; Yan F; Chen Y; Xu Y; Xia Q; Zhang X
    Clin Interv Aging; 2022; 17():567-576. PubMed ID: 35480963
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The association of C-reactive protein with responses to escitalopram antidepressant treatment in patients with major depressive disorder.
    Zhou J; Zhou J; Sun Z; Feng L; Feng Y; Xiao L; Chen X; Yang J
    J Affect Disord; 2022 Jun; 306():32-38. PubMed ID: 35271871
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A double-blind placebo-controlled trial of minocycline on translocator protein distribution volume in treatment-resistant major depressive disorder.
    Attwells S; Setiawan E; Rusjan PM; Xu C; Kish SJ; Vasdev N; Houle S; Santhirakumar A; Meyer JH
    Transl Psychiatry; 2021 May; 11(1):334. PubMed ID: 34052828
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial.
    Taraz M; Khatami MR; Dashti-Khavidaki S; Akhonzadeh S; Noorbala AA; Ghaeli P; Taraz S
    Int Immunopharmacol; 2013 Nov; 17(3):917-23. PubMed ID: 24121064
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Role of Inflammatory Proteins in Anti-Glucocorticoid Therapy for Treatment-Resistant Depression.
    Strawbridge R; Jamieson A; Hodsoll J; Ferrier IN; McAllister-Williams RH; Powell TR; Young AH; Cleare AJ; Watson S
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33669254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study.
    Kanchanatawan B; Tangwongchai S; Sughondhabhirom A; Suppapitiporn S; Hemrunrojn S; Carvalho AF; Maes M
    Neurotox Res; 2018 Apr; 33(3):621-633. PubMed ID: 29327213
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inflammatory markers and treatment outcome in treatment resistant depression: A systematic review.
    Yang C; Wardenaar KJ; Bosker FJ; Li J; Schoevers RA
    J Affect Disord; 2019 Oct; 257():640-649. PubMed ID: 31357161
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of Minocycline as an Adjunct Neuroinflammatory Modulator in Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials.
    Al Jumaili W; Vora D; Trivedi C; Jain S
    Prim Care Companion CNS Disord; 2023 Sep; 25(5):. PubMed ID: 37713730
    [No Abstract]   [Full Text] [Related]  

  • 59. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study.
    Rapaport MH; Nierenberg AA; Schettler PJ; Kinkead B; Cardoos A; Walker R; Mischoulon D
    Mol Psychiatry; 2016 Jan; 21(1):71-9. PubMed ID: 25802980
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.